Table 4 The clinicopathologic features, molecular findings, and treatment/follow-up data for a multi-institutional cohort of 23 RAS-amplified mCRC.
Case | Age (years) | Sex | History of IBD | Primary colonic origin | Histologic subtype | Histologic grade | RAS gene amplification (CN)a | MMR protein status | Anti-EGFR treatment | Follow-up (months) |
|---|---|---|---|---|---|---|---|---|---|---|
1 | 73 | F | No | Cecum | Conventional | Poor | KRAS (14) | Preserved | Yes (panitumumab)b | DOD (12) |
2 | 38 | F | Yes (UC) | Sigmoid | Conventional | Poor | KRAS (6) | Preserved | No | AWD (27) |
3 | 34 | F | No | Rectum | Conventional | Poor | KRAS (16) | Preserved | Yes (cetuximab)b | AWD (46) |
4 | 33 | M | No | Rectum | Conventional | Moderate | KRAS (7) | Preserved | No | DOD (26) |
5 | 57 | M | No | Rectosigmoid | Conventional | Moderate | KRAS (7) | Preserved | Yes (cetuximab)b | DOD (3) |
6 | 67 | M | No | Splenic flexure | Conventional | Moderate | KRAS (42) | Preserved | Yes (cetuximab)b | AWD (52) |
7 | 49 | M | No | Rectum | Conventional | Moderate | KRAS (7) | Preserved | No | AWD (47) |
8 | 38 | M | Yes (UC) | Rectum | Mucinous and signet-ring cell | Poor | KRAS (7) | Preserved | Yes (panitumumab)b | DOD (14) |
9 | 55 | M | No | Sigmoid | Conventional | Poor | KRAS (7) | Preserved | No | DOD (14) |
10 | 63 | F | No | Sigmoid | Signet-ring cell | Poor | KRAS (7) | Preserved | No | DOD (12) |
11 | 56 | M | No | Rectum | Conventional | Poor | KRAS (7) | Preserved | Yes (cetuximab)b | AWD (12) |
12 | 48 | F | No | Rectum | Conventional | Moderate | KRAS (7) | Preserved | No | AWD (21) |
13 | 42 | M | Yes (UC) | Hepatic flexure | Mucinous | Moderate | KRAS (7) | Preserved | No | NED (16) |
14 | 55 | M | No | Rectum | Conventional | Moderate | KRAS (7) | Preserved | No | AWD (11) |
15 | 48 | M | No | Rectum | Conventional | Moderate | KRAS (7) | Preserved | No | AWD (103) |
16 | 64 | F | Yes (UC) | Sigmoid | Signet-ring cell | Poor | KRAS (7) | Preserved | No | AWD (11) |
17 | 54 | M | No | Sigmoid | Conventional | Moderate | KRAS (7) | Preserved | Yes (cetuximab)b | AWD (31) |
18 | 61 | F | No | Rectosigmoid | Conventional | Moderate | KRAS (7) | Preserved | No | AWD (76) |
19 | 46 | M | No | Cecum | Conventional | Poor | KRAS (7) | Preserved | No | AWD (6) |
20 | 56 | F | No | Sigmoid | Conventional | Moderate | KRAS (7); NRAS (7) | Preserved | Yes (cetuximab)b | AWD (6) |
21 | 66 | M | No | Sigmoid | Conventional | Moderate | NRAS (7) | Preserved | No | DOD (18) |
22 | 81 | M | No | Rectosigmoid | Conventional | Moderate | KRAS (8) | Preserved | No | AWD (8) |
23 | 49 | F | Yes (UC) | Rectum | Mucinous | Moderate | KRAS (10) | Preserved | No | DOD (20) |
